Kiniksa Pharmaceuticals International (KNSA) EBITDA (2017 - 2026)

Kiniksa Pharmaceuticals International has reported EBITDA for 10 years, with the latest figure at $22.0 million in Q1 2026.

• For the quarter ending Q1 2026, EBITDA rose 157.14% year-over-year to $22.0 million; the trailing twelve-month figure through Mar 2026 stood at $72.6 million (up 525.26% YoY), and the FY2025 full-year result was $59.1 million, up 236.39% from the prior year.
• EBITDA for Q1 2026 stood at $22.0 million, up from $14.3 million in the prior quarter.
• The five-year high for EBITDA was $224.1 million in Q3 2022, with the low at -$25.2 million in Q1 2022.
• Historically, EBITDA has averaged $13.8 million across 5 years, with a median of $4.6 million in 2022.
• Annual changes were most pronounced in 2022 — EBITDA soared 832.01% — and 2024, when it plunged 135.69%.
• Kiniksa Pharmaceuticals International's EBITDA stood at $4.6 million in 2022, then jumped by 451.78% to $25.2 million in 2023, then sank by 135.69% to -$9.0 million in 2024, then surged by 259.03% to $14.3 million in 2025, then soared by 53.2% to $22.0 million in 2026.
• The last three EBITDA figures came in at $22.0 million (Q1 2026), $14.3 million (Q4 2025), and $18.3 million (Q3 2025), per Business Quant data.